Maladies inflammatoires de l'intestin [Inflammatory bowel diseases].

Détails

ID Serval
serval:BIB_A65211EA6FD3
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Maladies inflammatoires de l'intestin [Inflammatory bowel diseases].
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Felley C., Guyot J., Hess J., Mottet C., Delarive J., Michetti P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
01/2005
Volume
1
Numéro
3
Pages
218-20, 223-7
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
COX-2 specific anti-inflammatory agents appear as able to induce a flare of inflammatory bowel disease as classical anti-inflammatory agents. The use of steroids, immunomodulators or infliximab prior to surgery does not appear to increase post-operative complication rates. Cases of hepatitis B reactivation have been described after infliximab therapy, suggesting that hepatitis B serological status should be verified prior to infliximab therapy. Adalimubab, a fully humanized antibody directed against TNF-alpha, is efficacious in patients that have lost response or did not tolerate infliximab. Approval of this agent is still awaited. Leucoapheresis is a promising tool in ulcerative colitis.
Mots-clé
Humans, Immunologic Factors/therapeutic use, Immunosuppressive Agents/therapeutic use, Inflammatory Bowel Diseases/complications, Inflammatory Bowel Diseases/drug therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Création de la notice
25/01/2008 15:58
Dernière modification de la notice
20/08/2019 15:11
Données d'usage